Cue Biopharma, Inc.

CUE

Exchange: Nasdaq
Industry: Pharmaceutical Preparations
SEC CIK: 0001645460

SEC filings (opens in a new tab)

Insider trades, last 90 days

0 buys · 3 sells

Sold $2.04M
Open-market purchases (P) and sales (S), counted by Form 4 filing.

View insider trades

13F holders, Q2 2026

50

−7 vs. Q1 2026
Total value $52.25M

View 13F holders

Superinvestors holding CUE

0

None of the superinvestors held CUE at the end of Q2 2026.

See all holders

Price chart

Chart by TradingView (opens in a new tab)

Latest insider trades

Open-market purchases and sales by CUE insiders, newest first.

Insider trades
Filed (ET)	Trade date	Insider	Transaction	Shares	Avg price	Value	Shares after	Holding change	Filing
Aug 17, 20266:22 PM ET	Aug 13, 2026	Ray SumitaChief Legal Compliance Officer	SSaleCommon Stock	−8.83K	$30.0858	−$265.63K	118.55K	−6.9%	SEC
Aug 17, 20266:19 PM ET	Aug 13, 2026	Meluzio Michael VincentVP, Prin. Accounting Officer	SSaleCommon Stock	−5.63K	$30.0859	−$169.32K	48.96K	−10.3%	SEC
Aug 14, 20268:46 PM ET	Aug 12 – Aug 13, 2026	Lin Shao-LeeChief Executive Officer	SSaleCommon Stock	−58.26K	$27.5767	−$1.61M	706K	−7.6%	SEC
Jan 2, 20264:00 PM ET	Dec 30, 2025	Sarraf PashaDirector	PPurchaseCommon Stock	+323.86K	$0.308	+$99.75K	323.86K	New position	SEC
Dec 18, 2024	Dec 16, 2024	PASSERI DANIEL RCHIEF EXECUTIVE OFFICER	PPurchaseCommon Stock	+30K	$1.03	+$30.9K	164.58K	+22.3%	SEC

Top 5 13F holders, Q2 2026

The largest institutional positions in CUE at the end of Q2 2026.

Institutions holding CUE in Q2 2026
Institution	Shares	Value	% of portfolio	Change in shares	Action
Bleichroeder LP	370,682	$11.7M	2.09%	−6,448,482−94.6%	Reduced
DRIEHAUS CAPITAL MANAGEMENT LLC	292,144	$9.22M	0.05%	+292,144	New
VANGUARD CAPITAL MANAGEMENT LLC	161,700	$5.1M	0.00%	−2,295,752−93.4%	Reduced
Ikarian Capital, LLC	104,364	$3.29M	0.54%	+104,364	New
Polygon Management Ltd.	93,819	$2.96M	0.48%	+93,819	New